#894 Baseline data of the multiECCO2R study: a safety and efficiency study to evaluate CO2 removal in combination with continuous veno-venous hemodialysis/hemodiafiltration therapy

Abstract Background and Aims Extracorporeal carbon dioxide removal (ECCO2R) therapy was proposed to reduce the level of blood CO2 and the risk of ventilator-induced lung injury in patients with combined renal failure and hypercapnia due to acute lung failure. The utilization of CO2 removal gas exchangers enables non-invasive ventilation techniques or protective invasive mechanical ventilation, thereby minimizing pulmonary stress. The multiECCO2R blood gas exchanger featuring a surface of 1.35 m2 can be integrated into a CRRT platform downstream of the dialyzer, facilitating the simultaneous treatment of adult patients with ARDS and acute kidney injury. Method The open, interventional post-market clinical follow-up study has progressed through an interim analysis and is now in the final analysis phase. 28 patients with combined renal failure and hypercapnia due to acute lung failure in COVID-19 and other forms of respiratory insufficiency (e.g. ARDS) have been recruited and treated on the multiFiltrate (MFT)/MFT PRO with the multiECCO2R gas exchanger (EUROSETS) for up to 72 hours. Results 17 patients (12 males) have been included in the interim analysis with a mean age of 66.8 ± 11.3 years and a baseline paCO2 value of 59.2 ± 8.3 mmHg treated with best possible protective ventilation setting. The leading cause for renal disease was sepsis (42.1%), and the leading cause for lung disease was pneumonia (50%). All included patients were treated in a CVVHD setting, with a mean blood flow of 186.5 ± 75.3 ml/h and anticoagulation with heparin (47.1%) or citrate (52.9%). Conclusion The multiECCO2R study evaluates safety and efficiency of CO2 removal in combination with CRRT treatment. The recruitment phase has been completed by the end of 2024. Trial results are planned to be reported in second quarter of 2025.